Raymond James Reiterates Strong Buy Rating on Rapport Therapeutics (RAPP)

May 7, 2026 8:56 AM

Raymond James analyst Tiago Fauth reiterated a Strong Buy rating and $66.00 price target on Rapport Therapeutics (NASDAQ: RAPP).The analyst ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found